The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

At the recently concluded North American Neuromodulation Society annual meeting, Boston presented a total of 17 abstracts.

At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, ...